exPDite-2: A Phase 3 Study to Assess the Efficacy and Safety of Midbrain Dopaminergic Neuronal Cell Therapy (Bemdaneprocel) for Participants With Parkinsons Disease

Date Added
January 27th, 2026
PRO Number
Pro00147082
Researcher
Andrew Ameri

List of Studies

Keywords
Movement Disorders, Parkinsons
Summary

This study will test if bemdaneprocel (the "study drug") is safe and effective in improving symptoms in participants with Parkinson's Disease. The symptoms of PD are due to a loss of cells that make a specific chemical in your brain called dopamine. The study drug is a cell therapy that contains live brain cells that produce dopamine. This study will last 5 to 8 years, and depending on randomization group between 23-32 study visits.

Institution
MUSC
Recruitment Contact
Sandra Wilson
843-792-4616
wilsosan@musc.edu



-- OR --